Walleye Capital LLC Acquires Shares of 32,576 Brainsway Ltd. Sponsored ADR $BWAY

Posted by on Jul 25th, 2026

Walleye Capital LLC bought a new position in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY – Free Report) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 32,576 shares of the company’s stock, valued at approximately $433,000. Walleye Capital LLC owned approximately 0.08% of Brainsway at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Goldman Sachs Group Inc. increased its holdings in shares of Brainsway by 2.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 25,738 shares of the company’s stock valued at $490,000 after purchasing an additional 589 shares in the last quarter. Man Group plc lifted its holdings in Brainsway by 4.5% during the 4th quarter. Man Group plc now owns 18,027 shares of the company’s stock worth $343,000 after buying an additional 782 shares in the last quarter. NewEdge Advisors LLC lifted its holdings in Brainsway by 7.4% during the 3rd quarter. NewEdge Advisors LLC now owns 28,629 shares of the company’s stock worth $431,000 after buying an additional 1,964 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in Brainsway in the 1st quarter valued at $40,000. Finally, Palumbo Wealth Management LLC boosted its position in Brainsway by 37.9% in the 4th quarter. Palumbo Wealth Management LLC now owns 16,320 shares of the company’s stock valued at $310,000 after buying an additional 4,483 shares during the last quarter. 30.11% of the stock is owned by institutional investors.

Brainsway Stock Performance

Shares of NASDAQ:BWAY opened at $15.97 on Friday. The company has a 50 day moving average price of $15.02 and a two-hundred day moving average price of $13.95. The company has a market capitalization of $640.86 million, a PE ratio of 45.63 and a beta of 1.22. Brainsway Ltd. Sponsored ADR has a 52 week low of $5.68 and a 52 week high of $17.35.

Brainsway (NASDAQ:BWAY – Get Free Report) last announced its quarterly earnings results on Wednesday, May 13th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.07. Brainsway had a net margin of 15.68% and a return on equity of 12.28%. The company had revenue of $15.53 million for the quarter, compared to analysts’ expectations of $14.63 million. On average, sell-side analysts forecast that Brainsway Ltd. Sponsored ADR will post 0.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on BWAY shares. BTIG Research started coverage on Brainsway in a research report on Monday, July 20th. They set a “buy” rating and a $18.00 target price for the company. Wall Street Zen cut Brainsway from a “buy” rating to a “hold” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Brainsway in a research report on Friday, July 17th. Weiss Ratings reissued a “buy (b-)” rating on shares of Brainsway in a report on Tuesday. Finally, New Street Research restated a “buy” rating on shares of Brainsway in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating and five have issued a Buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $15.67.

View Our Latest Analysis on Brainsway

About Brainsway

(Free Report)

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.

Read More

Want to see what other hedge funds are holding BWAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY – Free Report).

Institutional Ownership by Quarter for Brainsway (NASDAQ:BWAY)

Receive News & Ratings for Brainsway Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainsway and related companies with MarketBeat.com's FREE daily email newsletter.